Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated her Overweight rating on Surgery Partners (NASDAQ:SGRY) and maintained a price target of $43.
September 14, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Surgery Partners, maintaining a price target of $43.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Surgery Partners. The maintained price target of $43 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100